GLPG - Galapagos NV - ADR
IEX Last Trade
29.12
-0.640 -2.198%
Share volume: 82,476
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$29.76
-0.64
-2.15%
Fundamental analysis
20%
Profitability
13%
Dept financing
12%
Liquidity
75%
Performance
14%
Performance
5 Days
12.48%
1 Month
5.32%
3 Months
6.05%
6 Months
-19.29%
1 Year
-22.84%
2 Year
-41.75%
Key data
Stock price
$29.12
DAY RANGE
N/A - N/A
52 WEEK RANGE
$24.16 - $42.46
52 WEEK CHANGE
-$0.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Paul Stoffels
Region: US
Website: http://www.glpg.com/
Employees: 1,304
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.glpg.com/
Employees: 1,304
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.
Recent news